Articles

  • Dec 1, 2024 | pharmaceuticalintelligence.com | Sudipta Saha

    The study published in Journal of Functional Foods explores the molecular mechanisms underlying chicoric acid’s (CA) role in glucose metabolism. Chicoric acid, a natural polyphenolic compound found in plants like chicory and basil, has garnered attention for its anti-inflammatory and antidiabetic properties. The researchers investigated its potential to regulate glucose uptake and insulin sensitivity, focusing on the AMP-activated protein kinase (AMPK) pathway.

  • Nov 26, 2024 | pharmaceuticalintelligence.com | Sudipta Saha

    Joint Convenor: Dr. Sudipta Saha (Member of LPBI since 2012) About the Conference: The International Conference on ‘Symphony of Cellular Signals in Metabolism and Immune Response’ focuses on the complex signalling pathways governing cellular functions in health and disease. It will explore the cellular mechanisms that regulate metabolism, immune responses, and survival, highlighting advances in medical science and biotechnology.

  • Oct 24, 2024 | pharmaceuticalintelligence.com | Sudipta Saha

    In the search for dietary approaches to prevent and fight cancer, certain foods have been found to possess potent anti-cancer properties. These foods not only help reduce the risk of cancer but also assist in repairing the body. Five such foods are green tea, broccoli like vetables, papaya, purple potatoes, and pomegranate—and the bioactive compounds responsible for their benefits.

  • Oct 22, 2024 | pharmaceuticalintelligence.com | Sudipta Saha

    The 2024 World Medical Innovation Forum (WMIF) spotlighted xenotransplantation as a transformative solution to the organ shortage crisis. By leveraging genetically modified pig organs, this emerging field offers a new source of transplants, expanding life-saving care options. Key breakthroughs in 2024 have brought new hope for patients, but significant hurdles remain, including immunological rejection.

  • Sep 17, 2024 | pharmaceuticalintelligence.com | Sudipta Saha

    Immunotherapy with pembrolizumab boosts post-surgical outcomes in high-risk bladder cancer patients September 16, 2024 by Dr. Sudipta Saha A large clinical trial has shown that pembrolizumab (Keytruda), an immunotherapy drug, nearly doubles the cancer-free survival time for patients with high-risk, muscle-invasive bladder cancer following surgery.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →